These terms and conditions govern your use of the website alphaminr.com and its related
services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr,
(“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms
include the provisions in this document as well as those in the Privacy Policy. These terms may
be modified at any time.
Subscription
Your subscription will be on a month to month basis and automatically renew every month. You may
terminate your subscription at any time through your account.
Fees
We will provide you with advance notice of any change in fees.
Usage
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Limitation of Liability
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The
service is provided “As is”. The materials and information accessible through the Service are
solely for informational purposes. While we strive to provide good information and data, we make
no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO
YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY
OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR
(2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE
CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR
CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision
shall not affect the validity or enforceability of the remaining provisions herein.
Privacy Policy
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal
information when we provide our service (“Service”). This Privacy Policy explains how
information is collected about you either directly or indirectly. By using our service, you
acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy
Policy, please do not use our Service. You should contact us if you have questions about it. We
may modify this Privacy Policy periodically.
Personal Information
When you register for our Service, we collect information from you such as your name, email
address and credit card information.
Usage
Like many other websites we use “cookies”, which are small text files that are stored on your
computer or other device that record your preferences and actions, including how you use the
website. You can set your browser or device to refuse all cookies or to alert you when a cookie
is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not
function properly. We collect information when you use our Service. This includes which pages
you visit.
Sharing of Personal Information
We use Google Analytics and we use Stripe for payment processing. We will not share the
information we collect with third parties for promotional purposes.
We may share personal information with law enforcement as required or permitted by law.
☑
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended:
June 27,
2025
Or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number:
0-11634
STAAR Surgical Co
mpany
(Exact Name of Registrant as Specified in its Charter)
Delaware
95-3797439
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
25510 Commercentre Drive
Lake Forest
,
California
92630
(Address of Principal Executive Offices)
(Zip Code)
(
626
)
303-7902
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
STAA
NASDAQ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
☑
No
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
☑
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
☐
No
☑
The registrant has
49,553,035
shares of common stock, par value $0.01 per share, issued and outstanding as of July 30, 2025.
Investments available for sale (amortized cost basis of $
22,755
and $
86,346
at June 27, 2025 and December 27, 2024, respectively)
22,752
86,335
Accounts receivable trade, net of allowance for credit losses of
$
96
and $
32
at June 27, 2025 and December 27, 2024, respectively
34,440
77,897
Inventories, net
53,107
43,305
Prepayments, deposits and other current assets
15,362
16,244
Total current assets
292,792
367,940
Property, plant and equipment, net
74,417
84,889
Finance lease right-of-use assets, net
—
37
Operating lease right-of-use assets, net
33,027
36,850
Goodwill
1,786
1,786
Deferred income taxes
11,893
788
Other assets
23,866
17,234
Total assets
$
437,781
$
509,524
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
12,345
$
16,704
Obligations under finance leases
—
42
Obligations under operating leases
5,103
3,894
Allowance for sales returns
4,726
6,579
Other current liabilities
37,054
43,087
Total current liabilities
59,228
70,306
Obligations under operating leases
35,417
34,807
Deferred income taxes
—
297
Asset retirement obligations
45
42
Pension liability
6,518
6,737
Total liabilities
101,208
112,189
Commitments and contingencies
Stockholders’ equity:
Common stock, $
0.01
par value;
60,000
shares authorized:
49,546
and
49,294
shares issued and outstanding at June 27, 2025 and
December 27, 2024, respectively
495
493
Additional paid-in capital
484,801
471,449
Treasury stock,
261
and
0
shares at June 27, 2025 and December 27, 2024, respectively
(
4,479
)
—
Accumulated other comprehensive loss
(
5,645
)
(
7,031
)
Accumulated deficit
(
138,599
)
(
67,576
)
Total stockholders’ equity
336,573
397,335
Total liabilities and stockholders’ equity
$
437,781
$
509,524
See accompanying notes to the condensed consolidated financial statements.
1
STAAR SURGICAL COMPANY
CONDENSED CONSOLIDATED S
TATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Net sales
$
44,320
$
99,005
$
86,909
$
176,361
Cost of sales
11,521
20,593
26,105
36,914
Gross profit
32,799
78,412
60,804
139,447
Selling, general and administrative expenses:
General and administrative
20,969
23,641
45,427
46,869
Selling and marketing
26,283
31,005
53,228
59,663
Research and development
10,263
11,868
21,602
23,298
Restructuring, impairment and related charges
5,248
—
27,912
—
Total selling, general and administrative expenses
62,763
66,514
148,169
129,830
Operating income (loss)
(
29,964
)
11,898
(
87,365
)
9,617
Other income (expense), net:
Interest income, net
1,366
1,422
2,732
2,951
Gain (loss) on foreign currency transactions
2,563
(
3,049
)
3,981
(
5,346
)
Royalty income
—
—
—
508
Other income, net
120
63
251
393
Total other income (expense), net
4,049
(
1,564
)
6,964
(
1,494
)
Income (loss) before income taxes
(
25,915
)
10,334
(
80,401
)
8,123
Provision (benefit) for income taxes
(
9,103
)
2,955
(
9,378
)
4,083
Net income (loss)
$
(
16,812
)
$
7,379
$
(
71,023
)
$
4,040
Net income(loss) per share:
Basic
$
(
0.34
)
$
0.15
$
(
1.44
)
$
0.08
Diluted
$
(
0.34
)
$
0.15
$
(
1.44
)
$
0.08
Weighted average shares outstanding:
Basic
49,520
49,127
49,432
49,018
Diluted
49,520
49,811
49,432
49,529
See accompanying notes to the condensed consolidated financial statements.
2
STAAR SURGICAL COMPANY
CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Net income (loss)
$
(
16,812
)
$
7,379
$
(
71,023
)
$
4,040
Other comprehensive income (loss):
Defined benefit plans:
Net change in plan assets
(
620
)
(
97
)
330
135
Reclassification into other income (expense), net
16
(
17
)
32
(
34
)
Investments available for sale:
Change in unrealized gain (loss)
9
3
8
(
33
)
Reclassification into other income (expense), net
1
(
1
)
1
2
Foreign currency translation gain (loss)
704
(
938
)
1,505
(
2,038
)
Tax effect
(
151
)
299
(
490
)
618
Other comprehensive income (loss), net of tax
(
41
)
(
751
)
1,386
(
1,350
)
Comprehensive income (loss)
$
(
16,853
)
$
6,628
$
(
69,637
)
$
2,690
See accompanying notes to the condensed consolidated financial statements.
3
STAAR SURGICAL COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)
Three Months Ended
Common
Stock Shares
Common
Stock Par
Value
Additional
Paid-In
Capital
Treasury Stock Shares
Treasury Stock
Accumulated
Other
Compre-
hensive
Income
(Loss)
Accumulated
Deficit
Total
Balance, at March 28, 2025
49,523
$
495
$
476,868
—
$
—
$
(
5,604
)
$
(
121,787
)
$
349,972
Net loss
—
—
—
—
—
—
(
16,812
)
(
16,812
)
Other comprehensive loss
—
—
—
—
—
(
41
)
—
(
41
)
Common stock issued upon exercise of options
1
—
11
—
—
—
—
11
Stock-based compensation
—
—
7,994
—
—
—
—
7,994
Repurchase of common stock
—
—
(
261
)
(
4,479
)
—
—
(
4,479
)
Repurchase of employee common stock for taxes withheld
(
3
)
(
1
)
(
72
)
—
—
—
—
(
73
)
Vested restricted and performance stock units
25
1
—
—
—
—
—
1
Balance, at June 27, 2025
49,546
$
495
$
484,801
(
261
)
$
(
4,479
)
$
(
5,645
)
$
(
138,599
)
$
336,573
Balance at March 29, 2024
49,120
$
491
$
447,716
—
$
—
$
(
4,712
)
$
(
50,707
)
$
392,788
Net income
—
—
—
—
—
—
7,379
7,379
Other comprehensive loss
—
—
—
—
—
(
751
)
—
(
751
)
Common stock issued upon exercise of options
18
—
371
—
—
—
—
371
Stock-based compensation
—
—
9,482
—
—
—
—
9,482
Repurchase of employee common stock for taxes withheld
(
4
)
—
(
167
)
—
—
—
—
(
167
)
Unvested restricted stock
16
—
—
—
—
—
—
—
Forfeited restricted stock
(
1
)
—
—
—
—
—
—
—
Vested restricted and performance stock units
12
1
—
—
—
—
—
1
Balance at June 28, 2024
49,161
$
492
$
457,402
—
$
—
$
(
5,463
)
$
(
43,328
)
$
409,103
See accompanying notes to the condensed consolidated financial statements.
4
STAAR SURGICAL COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)
Six Months Ended
Common
Stock Shares
Common
Stock Par
Value
Additional
Paid-In
Capital
Treasury Stock Shares
Treasury Stock
Accumulated
Other
Compre-
hensive
Income
(Loss)
Accumulated
Deficit
Total
Balance, at December 27, 2024
49,294
$
493
$
471,449
—
$
—
$
(
7,031
)
$
(
67,576
)
$
397,335
Net loss
—
—
—
—
—
—
(
71,023
)
(
71,023
)
Other comprehensive income
—
—
—
—
—
1,386
—
1,386
Common stock issued upon exercise of options
53
1
386
—
—
—
—
387
Stock-based compensation
—
—
14,321
—
—
—
—
14,321
Repurchase of common stock
—
—
—
(
261
)
(
4,479
)
—
—
(
4,479
)
Repurchase of employee common stock for taxes withheld
(
69
)
(
1
)
(
1,355
)
—
—
—
—
(
1,356
)
Vested restricted and performance stock units
268
2
—
—
—
—
—
2
Balance, at June 27, 2025
49,546
$
495
$
484,801
(
261
)
$
(
4,479
)
$
(
5,645
)
$
(
138,599
)
$
336,573
Balance at December 29, 2023
48,839
$
488
$
436,947
—
$
—
$
(
4,113
)
$
(
47,368
)
$
385,954
Net income
—
—
—
—
—
—
4,040
4,040
Other comprehensive loss
—
—
—
—
—
(
1,350
)
—
(
1,350
)
Common stock issued upon exercise of options
205
2
5,693
—
—
—
—
5,695
Stock-based compensation
—
—
16,158
—
—
—
—
16,158
Repurchase of employee common stock for taxes withheld
(
40
)
—
(
1,396
)
—
—
—
—
(
1,396
)
Unvested restricted stock
16
—
—
—
—
—
—
—
Forfeited restricted stock
(
5
)
—
—
—
—
—
—
—
Vested restricted and performance stock units
146
2
—
—
—
—
—
2
Balance at June 28, 2024
49,161
$
492
$
457,402
—
$
—
$
(
5,463
)
$
(
43,328
)
$
409,103
See accompanying notes to the condensed consolidated financial statements.
5
STAAR SURGICAL COMPANY
CONDENSED CONSOLIDATED S
TATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Six Months Ended
June 27, 2025
June 28, 2024
Cash flows from operating activities:
Net income (loss)
$
(
71,023
)
$
4,040
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation of property, plant, and equipment
4,312
2,759
Non-cash operating lease expense
1,866
1,599
Impairment of fixed assets and operating lease right-of-use assets
14,593
—
Accretion/Amortization of investments available for sale
(
139
)
(
286
)
Deferred income taxes
(
10,624
)
60
Change in net pension liability
(
2
)
(
146
)
Loss on disposal of property and equipment
—
26
Stock-based compensation expense
13,817
15,381
Change in asset retirement obligation
—
20
Provision for sales returns and credit losses
(
1,818
)
1,079
Inventory provision
2,499
1,024
Changes in working capital:
Accounts receivable
43,859
436
Inventories
(
11,205
)
(
4,871
)
Prepayments, deposits, and other assets
(
6,264
)
(
7,085
)
Accounts payable
(
5,424
)
3,618
Other current and non-current liabilities
(
7,430
)
(
6,387
)
Net cash provided by (used in) operating activities
(
32,983
)
11,267
Cash flows from investing activities:
Acquisition of property and equipment
(
3,260
)
(
11,438
)
Purchase of investments available for sale
(
14,691
)
(
20,249
)
Proceeds from maturity of investments available for sale
77,560
26,356
Proceeds from sale of investments available for sale
862
850
Net cash provided by (used in) investing activities
60,471
(
4,481
)
Cash flows from financing activities:
Repayment of finance lease obligations
(
42
)
(
82
)
Repurchase of common stock
(
4,479
)
—
Repurchase of employee common stock for taxes withheld
(
1,356
)
(
1,396
)
Proceeds from the exercise of stock options
387
5,695
Proceeds from vested restricted and performance stock units
2
2
Net cash provided by (used in) financing activities
(
5,488
)
4,219
Effect of exchange rate changes on cash and cash equivalents
972
(
1,267
)
Increase in cash and cash equivalents
22,972
9,738
Cash and cash equivalents, at beginning of the year
144,159
183,038
Cash and cash equivalents, at end of the period
$
167,131
$
192,776
See accompanying notes to the condensed consolidated financial statements.
6
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 1 — Basis of Presentation and Significant Accounting Policies
STAAR Surgical Company, a Delaware corporation, was first incorporated in 1982, and together with its subsidiaries designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye.
The accompanying Condensed Consolidated Financial Statements present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of
December 27, 2024 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 27, 2024
.
The Condensed Consolidated Financial Statements for the three and six months ended June 27, 2025 and June 28, 2024, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and six months ended June 27, 2025 and June 28, 2024, are not necessarily indicative of the results to be expected for any other interim period or for the entire year.
Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks. Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.
Reclassifications
The Company reclassified certain personnel costs including salary-related and payroll tax expenses, bonus and stock-based compensation related expenses and travel related expenses previously included in research and development to sales and marketing. These costs support internal and external training and education of the Company’s existing products, and as such, the Company determined that classification of these costs in sales and marketing better reflects the nature of the costs and financial performance of the Company as it operates.
The Company has made certain
reclassification adjustments to conform prior period amounts to current presentation, which include reclassification adjustments between Research and development expenses and Sales and marketing expenses on its Condensed Consolidated Statements of Operations as follows (in thousands):
Three Months Ended June 28, 2024
Six Months Ended June 28, 2024
Prior Presentation
Reclassification
New Presentation
Prior Presentation
Reclassification
New Presentation
Sales and marketing
$
28,819
$
2,186
$
31,005
$
55,527
$
4,136
$
59,663
Research and development
14,054
(
2,186
)
11,868
27,434
(
4,136
)
23,298
The reclassification adjustments did not have a material impact on previously recorded amounts and had no impact on the Company’s Total selling, general and administrative expenses, Operating income (loss), Net income (loss) or Net earnings (loss) per share. The Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations, Comprehensive Income (Loss), Stockholders’ Equity and Cash Flows were not affected by changes in the presentation of these costs.
Additionally, non-cash lease expense is now presented on its own line in the Company’s Condensed Consolidated Statements of Cash Flows instead of combined with the changes in other current and non-current liabilities as follows (in thousands):
7
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 1 — Basis of Presentation and Significant Accounting Policies (Continued)
Reclassifications (Continued)
Six Months Ended June 28, 2024
Prior Presentation
Reclassification
New Presentation
Non-cash operating lease expense
$
—
$
1,599
$
1,599
Other current and non-current liabilities
(
4,788
)
(
1,599
)
(
6,387
)
Net cash provided by (used in) operating activities presented in the Condensed Consolidated Statements of Cash Flows was not affected by this change in presentation.
Restructuring, Impairment and Related Charges
In the first half of 2025, the Company took a number of steps to change its leadership team, realign its leadership structure to better address market needs, reduce costs and discretionary spending, and better position the Company to return to sustainable growth. As part of this leadership realignment and related efforts, during the three and six months ended June 27, 2025
, the Company recognized costs related to severance and reduction in workforce of $
3,645,000
and $
12,453,000
, respectively; consulting expenses of $
227,000
and $
866,000
, respectively; impairment expenses on leasehold improvements and machinery and equipment of $
700,000
and $
7,759,000
, respectively, as the Company will no longer be using these assets; and impairment on real property right-of-use assets of $
676,000
and $
4,083,000
, respectively, as the Company is actively pursuing subleasing opportunities for
two
of its leased properties. In addition, the Company also recognized impairment of $
0
and $
2,751,000
, respectively during the
three and six months ended June 27, 2025
for internally developed software that it will no longer be using as it will transition to a cloud-based software solution. An aggregate of $
5,248,000
and $
27,912,000
for such costs, expenses and charges is included in Restructuring, impairment and related charges on the Condensed Consolidated Statements of Operations for the
three and six months ended June 27, 2025. The restructuring effort was substantially completed as of June 27, 2025.
For more detail, see Notes 5, 7 and 8.
Vendor Concentration
There was one vendor that accounted for over
10
% of the Company’s consolidated accounts payable as of
June 27, 2025 and December 27, 2024.
Segment Reporting
The Company’s chief operating decision maker (“CODM”) has been identified as the
Chief Executive Officer
. The Company’s CODM manages and allocates resources to the operations of the Company on a consolidated basis.
The CODM assesses performance by comparing actual results to forecasts and decides how to allocate resources, i.e., headcount and compensation, based on consolidated net loss.
Significant segment expenses are consistent with those presented on the Condensed Consolidated Statements of Operations.
The measure of segment assets is reported on the balance sheet as total consolidated assets and the expenditures for additions to long-lived assets, and depreciation and amortization expense is consistent with those presented on the Condensed Statement of Cash Flows.
See “Note 14 – Disaggregation of Revenues, Geographic Sales and Product Sales” and “Note 15 – Geographic Assets” for specific information regarding the Company’s sales and long-lived assets.
8
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 1 — Basis of Presentation and Significant Accounting Policies (Continued)
Recent Accounting Pronouncements Not Yet Adopted
In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740).” ASU 2023-09 improves the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. It also includes certain other amendments to improve the effectiveness of income tax disclosures regarding (a) income or loss from continuing operations disaggregated between domestic and foreign and (b) income tax expense or benefit from continuing operations disaggregated by federal, state and foreign. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the disclosure requirements and its effect on the Condensed Consolidated Financial Statements.
In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40).” ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 requires footnote disclosure about specific expenses to disaggregate, in a tabular presentation, each relevant expense caption on the face of the income statement that includes any of the following natural expenses: (1) purchases of inventory, (2) employee compensation, (3) depreciation, (4) intangible asset amortization, and (5) depreciation, depletion and amortization recognized as part of oil- and gas-production activities or other types of depletion expenses. The tabular disclosure would also include certain other expenses, when applicable. ASU 2024-03 does not change or remove existing expense disclosure requirements; however, it may affect where that information appears in the footnotes to the financial statements. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company will adopt the annual disclosure requirements of ASU 2024-03 at the beginning of fiscal year 2026 and will adopt the interim disclosure requirement beginning fiscal year 2027. The Company is currently evaluating the disclosure requirements and its effect on the Condensed Consolidated Financial Statements.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law. The OBBBA makes permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the business interest expense limitation. ASC 740, “Income Taxes,” requires the effects of changes in tax rates and laws on deferred tax balances to be recognized in the period in which the legislation is enacted. The Company is currently evaluating the requirements and its effect on the Condensed Consolidated Financial Statements.
9
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 2 — Investments Available for Sale
Investments available for sale (“AFS”) and the related fair value measurement consisted of the following (dollars in thousands):
June 27, 2025
Fair Value Measurements
Amortized Cost
Unrealized Gains
Unrealized Losses
Estimated Fair Value
Level 1
Level 2
Commercial paper
$
4,153
$
1
$
—
$
4,154
$
—
$
4,154
Certificates of deposit
1,507
—
—
1,507
—
1,507
U.S. Treasury securities
999
—
—
999
999
—
Corporate debt securities
16,096
1
(
5
)
16,092
—
16,092
Total investments AFS
$
22,755
$
2
$
(
5
)
$
22,752
$
999
$
21,753
December 27, 2024
Fair Value Measurements
Amortized Cost
Unrealized Gains
Unrealized Losses
Estimated Fair Value
Level 1
Level 2
Commercial paper
$
21,466
$
4
$
(
2
)
$
21,468
$
—
$
21,468
Certificates of deposit
1,997
—
—
1,997
—
1,997
U.S. Treasury securities
11,356
3
(
4
)
11,355
11,355
—
Corporate debt securities
51,527
14
(
26
)
51,515
—
51,515
Total investments AFS
$
86,346
$
21
$
(
32
)
$
86,335
$
11,355
$
74,980
The Company obtains the fair value from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers and other industry and economic events.
The Company assessed each debt security in a gross unrealized loss position to determine whether the decline in fair value below amortized cost was a result of credit losses or other factors, whether the Company expects to recover the amortized cost of the debt security, the Company’s intent to sell and whether it is more-likely-than-not that the Company will not be required to sell the debt security before the recovery of the amortized cost basis. There has been
no
allowance for expected credit losses recorded for the
three and six months ended June 27, 2025 and the three and six months ended June 28, 2024.
The following table shows the fair value of investments AFS by contractual maturity (dollars in thousands):
As of June 27, 2025
Within one year
After one year through five years
Total
Commercial paper
$
4,154
$
—
$
4,154
Certificates of deposit
1,507
—
1,507
U.S. Treasury securities
999
—
999
Corporate debt securities
16,092
—
16,092
Total investments AFS
$
22,752
$
—
$
22,752
10
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 2 — Investments Available for Sale (Continued)
During the six months ended June 27, 2025
, two of the Company’s investments AFS with an aggregate fair value of $
862,000
, were subject to early redemption. The Company recognized a gain upon redemption of $
1,000
during the
six months ended June 27, 2025. During the six months ended June 28, 2024
, two of the Company’s investments AFS with an aggregate fair value of $
850,000
were subject to early redemption. The Company recognized a realized gain upon sale of $
3,000
during the
six months ended June 28, 2024
.
Note 3 — Inventories
Inventories, net are stated at the lower of cost and net realizable value, determined on a first-in, first-out basis and consisted of the following (in thousands):
June 27, 2025
December 27, 2024
Raw materials and purchased parts
$
10,353
$
9,705
Work in process
10,441
8,168
Finished goods
(1)
34,368
26,710
Total inventories, gross
55,162
44,583
Less inventory reserves
(
2,055
)
(
1,278
)
Total inventories, net
$
53,107
$
43,305
(1)
Finished goods inventory includes consigned inventory of
$
14,329,000
and $
1,958,000
at June 27, 2025 and December 27, 2024
, respectively. See also Note 14 for further details.
Note 4 — Prepayments, Deposits, and Other Current Assets
Prepayments, deposits, and other current assets consisted of the following (in thousands):
June 27, 2025
December 27, 2024
Prepayments and deposits
$
8,158
$
7,887
Prepaid rent
170
2,910
Prepaid insurance
1,210
2,432
Value added tax (VAT) receivable
2,640
1,359
BVG (Swiss Pension) prepayment
1,273
7
Other
(1)
1,911
1,649
Total prepayments, deposits and other current assets
$
15,362
$
16,244
(1)
No individual category in “Other” exceeds
5
% of the total prepayments, deposits and other current assets.
Note 5 — Property, Plant and Equipment
Property, plant and equipment, net consisted of the following (in thousands):
June 27, 2025
December 27, 2024
Machinery and equipment
$
43,487
$
46,113
Computer equipment and software
11,315
12,976
Furniture and fixtures
7,727
7,627
Leasehold improvements
18,671
19,766
Construction in process
30,551
32,014
Total property, plant and equipment, gross
111,751
118,496
Less accumulated depreciation
(
37,334
)
(
33,607
)
Total property, plant and equipment, net
$
74,417
$
84,889
11
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 5 — Property, Plant and Equipment (Continued)
As discussed in Note 1, during the three and six months ended June 27, 2025
, the Company recognized fixed asset impairment expense of $
700,000
and $
7,759,000
, respectively, primarily on leasehold improvements and machinery and equipment as the Company will no longer be using these assets. The Company also recognized impairment during the
three and six months ended June 27, 2025
of $
0
and $
2,751,000
, respectively, for internally developed software that the Company will no longer be using as it will transition to a cloud-based software solution. These amounts are recorded in Restructuring, impairment and related charges on the Condensed Consolidated Statement of Operations.
Construction in process primarily consists of the build out and validation of machinery and equipment.
The Company recorded depreciation expense in the following categories as follows (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Cost of sales
$
772
$
582
$
1,640
$
1,028
General and administrative
841
482
1,916
947
Selling and marketing
174
259
349
392
Research and development
188
162
370
318
Total depreciation expense
$
1,975
$
1,485
$
4,275
$
2,685
Note 6 – Cloud-Based Software
The Company capitalized cloud-based software implementation costs related to several systems, including enterprise resource planning and customer relationship management systems, which are recorded within Prepayments, deposits and other current assets or Other assets on the Condensed Consolidated Balance Sheets, depending upon the short- or long-term nature of such costs. Assets are expected to be placed into service throughout 2025 and 2026.
Capitalized cloud-based software costs, net consisted of the following (in thousands):
June 27, 2025
December 27, 2024
Capitalized cloud-based software
$
22,865
$
15,763
Less accumulated amortization
(
200
)
—
Total capitalized cloud-based software, net
$
22,665
$
15,763
Capitalized cloud-based software included in prepayments, deposits and other current assets
$
418
$
—
Capitalized cloud-based software included in other assets
$
22,247
$
15,763
Activity related to cloud-based software was as follows (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Additions to cloud-based software
$
4,934
$
3,157
$
7,101
$
5,697
Amortization of cloud-based software
147
—
200
—
12
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 7 – Other Current Liabilities
Other current liabilities consisted of the following (in thousands):
June 27, 2025
December 27, 2024
Accrued salaries and wages
$
13,821
$
16,140
Accrued bonuses
3,354
1,300
Severance payable
(1)
4,123
356
Accrued insurance
1,106
2,701
Income taxes payable
1,067
6,547
Marketing obligations
3,462
2,699
Other
(2)
10,121
13,344
Total other current liabilities
$
37,054
$
43,087
(1)
As discussed in Note 1, during the
six months ended June 27, 2025
, the Company recognized costs in connection with its leadership realignment and related efforts. Of these costs, a total of $
12,453,000
was recognized for severance costs related to leadership realignment and reduction in workforce. This amount is recorded in Restructuring, impairment and related charges on the Condensed Consolidated Statement of Operations. A majority of these severance payments were paid during the second quarter of 2025.
(2)
No individual category in “Other” exceeds
5
% of the other current liabilitie
s.
Note 8 – Operating Leases
The Company entered into operating leases primarily related to real property (office, manufacturing and warehouse facilities), automobiles and copiers. These operating leases are
two
to
ten years
in length with options to extend. The Company does not include any lease extensions in the initial valuation unless the Company was reasonably certain to extend the lease. Depending on the lease, there are those with fixed payment amounts for the entire length of the contract or payments which increase periodically as noted in the contract or increased at an inflation rate indicator. For operating leases that increase using an inflation rate indicator, the Company used the inflation rate at the time the lease was entered into for the length of the lease term.
Supplemental balance sheet information related to operating leases consisted of the following (in thousands):
June 27, 2025
December 27, 2024
Machinery and equipment
$
877
$
758
Computer equipment and software
446
446
Real property
44,450
47,648
Operating lease right-of-use assets, gross
45,773
48,852
Less accumulated depreciation
(
12,746
)
(
12,002
)
Operating lease right-of-use assets, net
$
33,027
$
36,850
Current operating lease obligations
$
5,103
$
3,894
Long-term operating lease obligations
35,417
34,807
Total operating lease liability
$
40,520
$
38,701
Weighted-average remaining lease term (in years)
6.8
7.1
Weighted-average discount rate
6.00
%
5.98
%
As discussed in Note 1, during the three and six months ended June 27, 2025
, the Company recognized impairment on real property right-of-use assets of $
676,000
and $
4,083,000
, respectively. The impairment relates to the Company’s decision to exit three of its leased properties, for which the Company has obtained a subtenant for one of its properties and is actively pursuing subleasing for the other two properties. The impairment was determined based on market comparables of similar subleased properties. The impairment is recorded in Restructuring, impairment and related charges on the Condensed Consolidated Statements of Operations.
13
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 8 – Operating Leases (Continued)
Supplemental cash flow information related to operating leases was as follows (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Operating lease cost
$
1,798
$
2,089
$
3,947
$
4,312
Cash paid for amounts included in the measurement of operating lease liabilities:
Operating cash flows
1,661
1,481
3,313
2,865
Right-of-use assets obtained in exchange for new operating lease liabilities
1,629
1,991
1,933
3,486
Future Maturities of Lease Liabilities
Estimated future maturities of lease liabilities under operating and finance leases having initial or remaining non-cancelable lease terms more than one year as of
June 27, 2025 is as follows (in thousands):
.
As of June 27, 2025
12 Months Ended
Operating Leases
June 2026
$
7,303
June 2027
8,041
June 2028
6,843
June 2029
6,923
June 2030
6,514
Thereafter
15,981
Total future minimum lease payments
51,605
Less amounts representing interest
(
11,085
)
Total lease liability
$
40,520
Note 9 — Income Taxes
The Company recorded an income tax provision as follows (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Provision (benefit) for income taxes
$
(
9,103
)
$
2,955
$
(
9,378
)
$
4,083
The effective tax rates for the three months ended June 27, 2025 and June 28, 2024
were
35.1
% and
28.6
%, respectively, and were
11.7
% and
50.3
% for the
six months ended June 27, 2025 and June 28, 2024
, respectively. The Company’s effective tax rates differ from the U.S. federal statutory rate of
21
% for the
three and six months ended June 27, 2025 and June 28, 2024
, respectively, primarily due to the income tax expense generated in foreign jurisdictions.
14
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 10 – Defined Benefit Pension Plans
The Company has defined benefit plans covering employees of its Switzerland and Japan operations. The following table summarizes the components of net periodic pension cost recorded for the Company’s defined benefit pension plans (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Service cost
(1)
$
436
$
313
$
840
$
638
Interest cost
(2)
63
87
125
171
Expected return on plan assets
(2)
(
139
)
(
136
)
(
274
)
(
268
)
Prior service credit
(2),(3)
(
53
)
(
45
)
(
106
)
(
90
)
Settlement gain
(2),(3)
(
4
)
—
(
8
)
—
Actuarial loss recognized in current period
(2),(3)
73
28
146
56
Net periodic pension cost
$
376
$
247
$
723
$
507
(1)
Recognized in selling general and administrative expenses on the Condensed Consolidated Statements of Operations.
(2)
Recognized in other income (expense), net on the Condensed Consolidated Statements of Operations.
(3)
Amounts reclassified from accumulated other comprehensive income (loss).
The Company currently is not required to and does not make contributions to its Japan pension plan. The Company’s contributions to its Swiss pension plan are as follows (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Employer contribution
$
357
$
272
$
622
$
539
Note 11 — Stockholders’ Equity
Incentive Plan
The Company maintains an Amended and Restated Omnibus Equity Incentive Plan, as amended (the “Equity Plan”). The Equity Plan allows for awards of stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”) and performance stock units (“PSUs”) and other stock- and cash-based awards, including awards that are subject to service-based and performance-based vesting conditions. As of June 27, 2025, the Company had outstanding grants of stock options, RSUs and PSUs.
Stock options granted under the Equity Plan are granted at fair market value on the date of grant, become exercisable generally over a
three-year
period, or as determined by the Board of Directors, and expire over periods not exceeding
10
years from the date of grant. Certain stock options and stock-based awards provide for accelerated vesting if there is a change in control and pre-established financial metrics are met (as defined in the Equity Plan). Grants of restricted stock outstanding under the Equity Plan generally vest over periods of
one
to
three years
. Grants of RSUs and PSUs outstanding under the Equity Plan generally vest based on service, performance, or a combination of both. On June 19, 2024, stockholders approved a proposal to increase the number of shares under the Equity Plan by
2,600,000
shares, for a total of
22,805,000
shares. As of
June 27, 2025
, there were
731,032
shares available for grant under the Equity Plan.
15
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 11 — Stockholders’ Equity (Continued)
Stock-Based Compensation
The cost that has been charged against income for stock-based compensation is set forth below (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Employee stock options
$
1,640
$
3,518
$
4,045
$
6,691
Restricted stock
145
170
302
198
RSUs
3,345
3,053
6,308
5,343
PSUs
2,211
2,119
2,607
2,804
Nonemployee stock options
208
151
302
292
Nonemployee RSUs
253
31
253
53
Total stock-based compensation expense
$
7,802
$
9,042
$
13,817
$
15,381
The Company recorded stock-based compensation costs in the following categories (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Cost of sales
$
90
$
363
$
380
$
661
General and administrative
4,643
4,981
7,326
8,056
Selling and marketing
1,309
1,319
2,586
2,529
Research and development
1,760
2,379
3,525
4,135
Total stock-based compensation expense, net
7,802
9,042
13,817
15,381
Amounts capitalized as part of inventory
192
440
504
777
Total stock-based compensation expense, gross
$
7,994
$
9,482
$
14,321
$
16,158
As of
June 27, 2025, total unrecognized compensation cost related to non-vested stock-based compensation arrangements were as follows (in thousands):
June 27, 2025
Stock options
$
9,026
RSUs and PSUs
40,468
Total unrecognized stock-based compensation cost
$
49,494
The cost is expected to be recognized over a weighted-average period of approximately
two
years
.
Assumptions
The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model applying the weighted-average assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock. The expected term of stock options granted is derived from the historical exercises and post-vesting cancellations and represents the period of time that stock options granted are expected to be outstanding. The Company has calculated a
8
% estimated forfeiture rate based on historical forfeiture experience.
The risk-free rate is based on the U.S. Treasury yield curve corresponding to the expected term at the time of the grant.
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Expected dividend yield
0
%
0
%
0
%
0
%
Expected volatility
60
%
59
%
60
%
59
%
Risk-free interest rate
4.03
%
4.45
%
4.09
%
4.19
%
Expected term (in years)
5.05
5.29
5.05
5.29
16
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 11 — Stockholders’ Equity (Continued)
Stock Options
A summary of stock option activity under the Equity Plan for the
six months ended June 27, 2025 is presented below:
Stock
Options
(in 000’s)
Weighted-
Average
Exercise
Price
Weighted-
Average
Remaining
Contractual
Term (years)
Aggregate
Intrinsic
Value
(in 000’s)
Outstanding at December 27, 2024
2,808
$
45.72
Granted
112
17.53
Exercised
(
53
)
7.23
Forfeited or expired
(
433
)
47.71
Outstanding at June 27, 2025
2,434
$
44.87
5.04
$
1,238
Exercisable at June 27, 2025
1,928
$
47.18
4.07
$
1,200
Restricted Stock, Restricted Stock Units and Performance Stock Units
A summary of restricted stock, RSU and PSU activity under the Equity Plan for the
six months ended June 27, 2025 is presented below (shares in thousands):
Restricted
Stock
RSUs
PSUs
Unvested at December 27, 2024
16
695
406
Granted
—
1,234
849
Vested
(
16
)
(
248
)
(
20
)
Forfeited or expired
—
(
151
)
(
417
)
Unvested at June 27, 2025
—
1,530
818
Share Repurchase Program
In May 2025, the Company’s Board of Directors authorized a share repurchase program under which the Company may repurchase up to $
30
million of its outstanding common stock.
Under the program, the Company may repurchase shares in the open market, through privately negotiated transactions, by entering into structured repurchase agreements with third parties, by making block purchases, and/or pursuant to Rule 10b5-1 trading plans. The timing, manner, price, and amount of any repurchases under the program will be determined by the Company in its discretion, subject to market conditions, legal requirements, and other considerations. The Company is not obligated to repurchase any specific number of shares, and the program may be modified, suspended, or discontinued at any time, without prior notice.
During the quarter ended June 27, 2025 the Company purchased
260,515
shares for an aggregate of $
4,479,000
pursuant to its share repurchase program. As of June 27, 2025, $
25,521,000
remained available for repurchases pursuant to the program. Subsequent to the end of the quarter, during the period June 28, 2025 to August 1, 2025, the Company purchased an additional
115,115
shares for a total of $
1,982,000
pursuant to its share repurchase program.
Repurchased shares are held in treasury stock. Treasury stock purchases are accounted for under the cost method whereby the cost of the acquired stock is recorded as treasury stock.
17
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 12 - Commitments and Contingencies
Litigation and Claims
From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business. These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability. The Company maintains insurance coverage for various matters, including product liability and certain securities claims. While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.
Note 13 — Basic and Diluted Net Income (Loss) Per Share
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share amounts):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Numerator:
Net income (loss)
$
(
16,812
)
$
7,379
$
(
71,023
)
$
4,040
Denominator:
Weighted average common shares:
Common shares outstanding
49,520
49,127
49,432
49,018
Denominator for basic calculation
49,520
49,127
49,432
49,018
Weighted average effects of potentially diluted common stock:
Stock options
—
468
—
407
Unvested restricted stock
—
7
—
6
RSUs
—
109
—
57
PSUs
—
100
—
41
Denominator for diluted calculation
49,520
49,811
49,432
49,529
Net income (loss) per share:
Basic
$
(
0.34
)
$
0.15
$
(
1.44
)
$
0.08
Diluted
$
(
0.34
)
$
0.15
$
(
1.44
)
$
0.08
Because the Company had a net loss for the three and six months ended June 27, 2025, the number of diluted shares is equal to the number of basic shares. The following table sets forth (in thousands) the weighted average number of options to purchase shares of common stock, restricted stock, RSUs and PSUs with either exercise prices or unrecognized compensation cost per share greater than the average market price per share of the Company’s common stock, which were not included in the calculation of diluted per share amounts because the effects would be anti-dilutive.
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Stock options
7,128
3,031
7,089
3,275
Restricted stock, RSUs and PSUs
1,009
180
885
63
Total
8,137
3,211
7,974
3,338
18
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 14 — Disaggregation of Sales, Geographic Sales and Product Sales
100
% of the Company’s sales are generated from the ophthalmic surgical product segment and the chief operating decision maker makes operating decisions and allocates resources based upon the consolidated operating results, and therefore the Company operates as
one
operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery. Historically the Company marketed and sold cataract intraocular lenses (“IOLs”) and related injectors and injector parts. The Company phased out sales of such products in fiscal 2023, and no longer intends to sell any such products. The composition of the Company’s net sales is primarily related to ICL sales.
ICL sales include normal recurring sales adjustments such as sales return allowances. In the following tables, sales are disaggregated by category and sales by geographic market data.
The Company maintains finished goods inventory at different sites in the United States, Switzerland and Japan, and from time to time, consigns or ships finished goods inventory to surgeons, hospitals, and distributors in advance of anticipated demand. The Company maintains title and risk of loss on consigned inventory and generally does not recognize revenue for consignment inventory until the Company is notified that the lenses have been implanted.
The following table disaggregates the Company’s consignment sales (in thousands):
The following breaks down sales into the following categories (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Non-consignment sales
$
37,525
$
94,775
$
75,376
$
166,539
Consignment sales
6,795
4,230
11,533
9,822
Total net sales
$
44,320
$
99,005
$
86,909
$
176,361
In April 2025, in order to mitigate potential financial exposure from tariffs imposed by China, the Company negotiated and implemented consignment agreements with its two distributors in China and delivered consigned inventory to its distributors. During the quarter ended June 27, 2025, the Company delivered additional consigned inventory to its distributors in China. As consigned inventory in China is purchased by the Company’s distributors, revenue associated with such consigned inventory will be recorded as consignment sales.
The Company markets and sells its products in over
75
countries and conducts its manufacturing in the United States. Sales are attributed to countries based on location of customers.
During 2025, the Company separately presented Korea as the sales exceeded
10
% of total sales and the presentation of immaterial amounts related to normal recurring sales adjustments previously presented in foreign other sales are presented in the countries these normal recurring sales adjustments are attributable to. Prior period amounts have been conformed to current presentation in the following table.
The composition of the Company’s net sales to unaffiliated customers was as follows (in thousands):
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Domestic
$
5,635
$
5,399
$
11,094
$
10,334
Foreign:
China
5,299
63,519
4,422
101,996
Japan
10,915
9,887
22,310
20,344
Korea
4,293
3,924
11,815
10,660
Other
(1)
18,178
16,276
37,268
33,027
Total foreign sales
38,685
93,606
75,815
166,027
Total net sales
$
44,320
$
99,005
$
86,909
$
176,361
(1)
No other location individually exceeds
10
% of the total sales.
The Company’s China distributors accounted for an aggregate of
12
% and
64
%
of net sales for the three months ended June 27, 2025 and June 28, 2024
, respectively. The Company’s Korea distributor accounted for an aggregate of
14
% of net sales for the
six months ended June 27, 2025
and the Company’s China distributors accounted for an aggregate of
58
% of net sales for the
six months ended June 28, 2024. As of December 27, 2024, the Company’s China distributors accounted for an aggregate of
58
% of consolidated trade receivables.
19
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 15 — Geographic Assets
The Company’s long-lived assets are located in the following geographical locations in which the Company operates. Other than the U.S. and Switzerland, no other geographic location exceeds
10
% of each category of long-lived assets. The composition of the Company’s long-lived assets was as follows (in thousands):
June 27, 2025
U.S.
Switzerland
Other
(1)
Total
Property, plant and equipment, net
$
57,007
$
16,926
$
484
$
74,417
Operating lease ROU assets, net
23,434
5,851
3,742
33,027
Total
$
80,441
$
22,777
$
4,226
$
107,444
December 27, 2024
U.S.
Switzerland
Other
(1)
Total
Property, plant and equipment, net
$
68,318
$
16,084
$
487
$
84,889
Finance lease ROU assets, net
37
—
—
37
Operating lease ROU assets, net
27,754
6,414
2,682
36,850
Total
$
96,109
$
22,498
$
3,169
$
121,776
(1)
No other location individually exceeds
10
% of each category of long-lived assets.
Note 16 — Subsequent Events
Proposed Merger with Alcon
On August 4, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alcon Research, LLC, a Delaware limited liability company (“Alcon”), and Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon (“Merger Sub”).
The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Alcon.
The Board of Directors has unanimously (a) determined that the Merger Agreement and the transactions contemplated thereby are fair to, and in the best interests of, the Company and its stockholders (b) approved and declared advisable the Merger Agreement and the transactions contemplated thereby and (c) resolved to recommend that the Company’s stockholders adopt the Merger Agreement. The stockholders of the Company will be asked to vote on the adoption of the Merger Agreement at a stockholder meeting that will be held on a date, and at a time and place, to be announced.
Under the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of common stock of the Company issued and outstanding immediately prior to the Effective Time (other than certain excluded shares as described in the Merger Agreement) will be cancelled and converted into the right to receive $
28.00
in cash, without interest.
The respective obligations of the Company, Alcon and Merger Sub to consummate the transactions contemplated by the Merger Agreement are subject to the satisfaction or waiver of a number of conditions, including: (1) the adoption of the Merger Agreement by the Company’s stockholders; (2) the absence of any law or order prohibiting consummation of the Merger in specified jurisdictions in which the Company, Alcon or their respective subsidiaries have business operations; (3) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and certain other specified regulatory approvals; (4) the accuracy of the other party’s representations and warranties, subject to certain materiality standards set forth in the Merger Agreement; and (5) compliance by the other party in all material respects with such other party’s obligations under the Merger Agreement. In addition, Alcon’s and Merger Sub’s obligation to consummate the transactions contemplated by the Merger Agreement are subject to the satisfaction or waiver of a condition that there has not occurred a material adverse effect on the Company since the date of the Merger Agreement that is continuing. The availability of financing is not a condition to the consummation of the Merger.
20
STAAR SURGICAL COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)
Note 16 — Subsequent Events (Continued)
If the Merger Agreement is terminated under specified circumstances, the Company may be required to pay Alcon a termination fee of up to $
43.4
million, and if the Merger Agreement is terminated under certain other circumstances, Alcon may be required to pay the Company a termination fee equal to $
72.4
million.
21
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and the Private Securities Litigation Reform Act of 1995, and is subject to the safe harbor created therein. In some cases readers can recognize forward-looking statements by the use of words like “anticipate,” “estimate,” “expect,” “project,” “intend,” “may,” “plan,” “believe,” “will,” “should,” “could,” “forecast,” “potential,” “continue,” “ongoing” (or the negative of those words and similar words or expressions), although not all forward-looking statements contain these words. Forward-looking statements include, without limitation, statements regarding the intent, belief or current expectations of the Company and its management regarding any of the following: demand for our implantable Collamer® lenses (“ICLs”); the benefits of our leadership realignment and related efforts; China macroeconomic conditions, procedure volumes, demand, and inventory levels; any projections of or guidance as to future earnings, revenue, sales, profit margins, expense rate, cash, effective tax rate, product mix, capital expense or any other financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; statements regarding new, existing, or improved products, including but not limited to, expectations for success of new, existing, and improved products in the U.S. or international markets or government approval of a new or improved products; commercialization of new or improved products; future economic conditions or size of market opportunities; expected costs of operations; statements of belief, including as to achieving business plans for 2025 and beyond; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, we caution investors and prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors, which if they do not materialize or prove correct, could cause actual results to differ materially from those expressed or implied by such forward-looking statements. We caution you not to place undue reliance on these forward-looking statements and to note they speak only as of the date hereof. Factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, without limitation, those described in our Annual Report on Form 10-K in “Item 1A. Risk Factors” filed on February 21, 2025. We disclaim any intention or obligation to update or review these financial projections or forward-looking statements due to new information or other events except as required by law.
The following discussion should be read in conjunction with the Company’s unaudited Condensed Consolidated Financial Statements, including the related notes, provided in this report.
We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
Overview
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. We generate worldwide revenue almost exclusively from sales of our implantable Collamer® lenses, or “ICLs.” Our ICLs are made from Collamer, which is a proprietary collagen copolymer material created and exclusively used by STAAR to make our lenses soft, flexible and biocompatible with the eye. Our ICLs are phakic lenses, meaning that they are implanted into the eye without removing the eye’s natural crystalline lens. This distinguishes an ICL procedure from other refractive procedures, as it does not involve the removal of corneal eye tissue. All of our ICLs are foldable, which allows the surgeon to insert them into the eye through a small incision during minimally invasive surgery. Further, while ICLs are intended to be permanent, our ICLs are reversible lens implants, meaning they can be removed by a doctor if desired.
STAAR employs a commercialization strategy that strives for sustainable profitable growth. Our growth strategy includes making our complete ICL product line available in our existing geographic markets and expanding into attractive markets where we do not sell our products today. In addition, we are focused on driving awareness of the ICL procedure and the clinical benefits of our ICLs, and providing surgeon training, support and education, particularly in our newer markets.
22
Business Environment and Factors Affecting Comparability
For the three months ended June 27, 2025, we reported $44.3 million of net sales, a decrease of 55% compared to $99.0 million of net sales for the three months ended June 28, 2024. This significant decrease is primarily due to dynamics within our business in China. Net sales to our two distributors in China were $5.3 million for the three months ended June 27, 2025, compared to net sales of $63.5 million for the three months ended June 28, 2024. During the three months ended June 27, 2025, our distributors in China purchased fewer ICLs, as they were able to satisfy procedural demand largely from their existing inventory. Our distributors in China have historically purchased products from us in bulk shipments in advance of anticipated demand, which they use to satisfy orders from hospital customers based on scheduled surgeries. During fiscal 2024, our distributors in China purchased lenses above contracted minimums in anticipation of higher procedural volumes during what is typically a summer “high season” in China. Due to dynamic macroeconomic conditions and other factors, the number of ICL procedures performed during the high season and the second half of 2024 overall was lower than expected. Accordingly, our distributors in China held, as of December 27, 2024, elevated levels of ICL product inventory. The level of inventory owned by our distributors in China has decreased substantially since December 27, 2024, and has now returned to historical levels. However, as anticipated we reported minimal China ICL sales in the first half of fiscal 2025. We expect our China revenue will normalize in the second half of fiscal 2025, as our distributors increase their purchases of ICLs to meet forecasted demand. However, our ability to successfully address these challenges will depend on a number of factors, including the risk of a prolonged slowdown or disruption in China and the status of trade tariffs both globally and between the United States and China.
In April 2025, in response to the announcement of tariffs by the United States on Chinese goods, China announced retaliatory tariffs on U.S.-origin goods. In order to mitigate potential financial exposure from such tariffs, we negotiated and implemented consignment agreements with our two distributors in China, and we delivered consigned inventory to China in advance of the implementation of tariffs. During the quarter ended June 27, 2025, we delivered additional consignment inventory to our distributors in China. While the tariff situation is evolving, we believe that these efforts to increase the amount of ICLs in China reduce the Company’s tariff risk in China in the near-term. In addition, we are rapidly ramping up our production capabilities in Switzerland to supplement our manufacturing capacity in the United States to provide optionality under multiple tariff scenarios.
Given that we now maintain consigned inventory in China, we believe that purchases by our distributors will largely be satisfied from our consigned inventory in-country in the near-term, rather than through bulk purchases. As a result, we expect our distributors will likely make more frequent purchases of ICLs in smaller quantities that are more closely aligned to actual procedural volumes as opposed to anticipated demand. We believe this will reduce the risk of elevated inventory buildup by our distributors, while at the same time maintaining sufficient ICL inventory in China to support quick and efficient delivery and fulfillment for surgical procedures.
Critical Accounting Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited Condensed Consolidated Financial Statements provided in this report, which we have prepared in accordance with U.S. generally accepted accounting principles. Preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual conditions may differ from our assumptions and actual results may differ from our estimates.
Management believes that there have been no significant changes during the six months ended June 27, 2025 to the items that we disclosed as our critical accounting estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 27, 2024.
23
Results of Operations
The following table shows the percentage of our total sales represented by certain items reflected in our Condensed Consolidated Statements of Income for the periods indicated.
Percentage of Net Sales for
Three Months Ended
Six Months Ended
June 27, 2025
June 28, 2024
June 27, 2025
June 28, 2024
Net sales
100.0
%
100.0
%
100.0
%
100.0
%
Cost of sales
26.0
%
20.8
%
30.0
%
20.9
%
Gross profit
74.0
%
79.2
%
70.0
%
79.1
%
General and administrative
47.3
%
23.9
%
52.3
%
26.6
%
Selling and marketing
59.3
%
31.3
%
61.2
%
33.8
%
Research and development
23.2
%
12.0
%
24.9
%
13.2
%
Restructuring, impairment and related charges
11.8
%
0.0
%
32.1
%
0.0
%
Total selling, general and administrative
141.6
%
67.2
%
170.5
%
73.6
%
Operating income (loss)
(67.6
)%
12.0
%
(100.5
)%
5.5
%
Total other income (expense), net
9.1
%
(1.6
)%
8.0
%
(0.8
)%
Income (loss) before income taxes
(58.5
)%
10.4
%
(92.5
)%
4.7
%
Provision (benefit) for income taxes
(20.5
)%
3.0
%
(10.8
)%
2.3
%
Net income (loss)
(38.0
)%
7.4
%
(81.7
)%
2.4
%
Net Sales
The following table presents our net sales (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Net sales
$
44,320
$
99,005
(55.2
)%
$
86,909
$
176,361
(50.7
)%
* Denotes change is greater than
+
100%.
Net sales for the three months ended June 27, 2025 decreased 55% from the same period of 2024 primarily due to decreased China sales. The composition of our net sales is primarily related to ICL sales. ICL sales include normal recurring sales adjustments such as sales return allowances. The sales decrease was driven by the Asia Pacific (“APAC”) region, which decreased 69%, with ICL unit decrease of 74%. The decrease in the APAC region was driven by decreased sales in China, partially offset by sales growth in India, Japan and Korea. We expect China sales to return to normalized levels beginning in the third quarter of 2025. The Europe, Middle East and Africa (“EMEA”) region sales increased 11% with ICL unit growth up 8%, due to sales growth in our distributor and direct markets. The Americas region sales increased 10% with ICL unit growth up 9%, due to sales growth in Canada, Latin America distributor markets and U.S. Changes in foreign currency favorably impacted net sales by $1.2 million.
Net sales for the six months ended June 27, 2025 decreased 51% from the same period of 2024 primarily due to decreased China sales. The sales decrease was driven by the APAC region, which decreased 66%, with ICL unit decrease of 69%. The decrease in the APAC region was driven by decreased sales in China, partially offset by sales growth in India, Korea and Japan. The EMEA region sales increased 14% with ICL unit growth up 9%, due to sales growth in our direct and distributor markets. The Americas region sales increased 10% with ICL unit growth up 6%, due to sales growth in Canada, Latin America distributor markets and U.S. Changes in foreign currency favorably impacted net sales by $0.4 million.
24
Gross Profit
The following table presents our gross profit and gross profit margin (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Gross profit
$
32,799
$
78,412
(58.2
)%
$
60,804
$
139,447
(56.4
)%
Gross margin
74.0
%
79.2
%
70.0
%
79.1
%
Gross profit for the three and six months ended June 27, 2025 decreased 58.2% and 56.4%, respectively, from the same period of 2024. Gross profit margin decreased to 74.0% of sales for the three months ended June 27, 2025 compared to 79.2% of sales for the three months ended June 28, 2024 due to decreased sales volume. Gross profit margin decreased to 70.0% of sales for the six months ended June 27, 2025 compared to 79.1% of sales for the six months ended June 28, 2024 due primarily to higher manufacturing costs per unit due to lower production volume and increased excess and obsolete inventory reserves, partially offset by decreased period costs as a result of our cost reductions implemented in the quarter ended March 28, 2025.
General and Administrative Expense
The following table presents our general and administrative expenses (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
General and administrative expense
$
20,969
$
23,641
(11.3
)%
$
45,427
$
46,869
(3.1
)%
Percentage of sales
47.3
%
23.9
%
52.3
%
26.6
%
General and administrative expenses for the three months ended June 27, 2025 decreased 11.3% from the same period of 2024 due to decreased outside services, partially offset by increased salary-related and payroll tax expenses. General and administrative expenses for the six months ended June 27, 2025 decreased 3.1% from the same period of 2024 due to decreased outside services and bonus and stock-based compensation expenses, partially offset by increased salary-related and payroll tax expenses and facilities related costs.
Selling and Marketing Expense
The following table presents our selling and marketing expenses (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Selling and marketing expense
$
26,283
$
31,005
(15.2
)%
$
53,228
$
59,663
(10.8
)%
Percentage of sales
59.3
%
31.3
%
61.2
%
33.8
%
Selling and marketing expenses for the three and six months ended June 28, 2024 decreased 15.2% and 10.8% from the same periods of 2024, respectively, due to decreased advertising and promotional activities, partially offset by increased salary-related and payroll tax expenses.
Research and Development Expense
The following table presents our research and development expenses (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Research and development expense
$
10,263
$
11,868
(13.5
)%
$
21,602
$
23,298
(7.3
)%
Percentage of sales
23.2
%
12.0
%
24.9
%
13.2
%
25
Research and development expenses for the three months ended June 27, 2025 decreased 13.5% due primarily to decreased stock-based compensation expenses. Research and development expenses for the six months ended June 27, 2025 decreased 7.3% due to decreased clinical expenses associated with U.S. post-approval clinical activities and stock-based compensation expenses.
Restructuring, Impairment and Related Charges
The following table presents our restructuring, impairment and related charges (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Restructuring, impairment and related charges
$
5,248
$
—
—
*
$
27,912
$
—
—
*
Percentage of sales
11.8
%
0.0
%
32.1
%
0.0
%
* Denotes change is greater than
+
100%.
In the first half of 2025, we took a number of steps to change our leadership team, realign our leadership structure to better address market needs, reduce costs and discretionary spending, and better position the Company to return to sustainable growth. As part of this leadership realignment and related efforts, during the three and six months ended June 27, 2025, we recognized costs related to severance and reduction in workforce of $3,645,000 and $12,453,000, respectively; consulting expenses of $227,000 and $866,000, respectively; impairment expenses on leasehold improvements and machinery and equipment of $700,000 and $7,759,000, respectively, as we will no longer be using these assets; and impairment on real property right-of-use assets of $676,000 and $4,083,000, respectively, as we are actively pursuing subleasing opportunities for two of our leased properties. In addition, we also recognized impairment of $0 and $2,751,000 during the three and six months ended June 27, 2025, respectively, for internally developed software that we will no longer be using as we will transition to a cloud-based software solution. The restructuring effort was substantially completed as of June 27, 2025.
Other Income (Expense), Net
The following table presents our other income (expense), net (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Other income (expense), net
$
4,049
$
(1,564
)
—
*
$
6,964
$
(1,494
)
—
*
Percentage of sales
9.1
%
(1.6
)%
8.0
%
(0.8
)%
* Denotes change is greater than
+
100%.
Other income (expense), net increased for the three and six months ended June 27, 2025 and June 28, 2024, primarily due to higher foreign exchange gains.
Income Taxes
The following table presents our income tax provision (dollars in thousands):
Three Months Ended
Percentage
Change
Six Months Ended
Percentage
Change
June 27, 2025
June 28, 2024
2025 vs. 2024
June 27, 2025
June 28, 2024
2025 vs. 2024
Income (benefit) tax provision
$
(9,103
)
$
2,955
—
*
$
(9,378
)
$
4,083
—
*
* Denotes change is greater than
+
100%.
The effective tax rates for the three months ended June 27, 2025 and June 28, 2024 were 35.1% and 28.6%, respectively. The effective tax rates for the six months ended June 27, 2025 and June 28, 2024 were 11.7% and 50.3%, respectively. Our effective tax rates differ from the U.S. federal statutory rate of 21%, primarily due to the income tax expense generated in foreign jurisdictions.
26
Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly.
Liquidity and Capital Resources
Our principal sources of liquidity are cash, cash equivalents, investments available for sale (“AFS”) and cash flow from operating activities. We believe these sources of liquidity will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the financial statements. We expect that cash flow from operating activities may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, working capital needs, capital expenditures, and capital deployment decisions. In addition, future capital requirements will depend on many factors including our growth rate in net sales, the timing and extent of spending to support our growth strategy, the expansion of selling and marketing activities, the timing of introductions of new products, as well as global macroeconomic factors. If our anticipated future cash flow from operating activities is insufficient to satisfy our future capital requirements in the long-term, we may need to seek additional capital. Our financial condition at June 27, 2025 and December 27, 2024 included the following (in thousands):
June 27, 2025
December
27, 2024
2025 vs. 2024
Cash and cash equivalents
$
167,131
$
144,159
$
22,972
Investments available for sale
22,752
86,335
(63,583
)
Total
$
189,883
$
230,494
$
(40,611
)
Current assets
$
292,792
$
367,940
$
(75,148
)
Current liabilities
59,228
70,306
(11,078
)
Working capital
$
233,564
$
297,634
$
(64,070
)
Cash and cash equivalents include cash and balances in deposits and money market accounts held at banks and financial institutions. Our investment policy’s primary objective is capital preservation while maximizing our return on investment. Investments available for sale may include U.S. government and corporate debt securities, commercial paper, certain certificates of deposit and related security types, that are rated by two nationally recognized statistical rating organizations with minimum investment grade ratings of AAA to A-/A-1+ to A-2, or the equivalent. The maturity of individual investments may not extend 24 months from the date of purchase. There are also limits to the amount of credit exposure in any given security type. We do not have any off-balance sheet arrangements.
A summary of cash flows for the six months ended June 27, 2025 and June 28, 2024 was as follows (in thousands):
Six Months Ended
June 27, 2025
June 28, 2024
Cash flows from:
Operating activities
$
(32,983
)
$
11,267
Investing activities
60,471
(4,481
)
Financing activities
(5,488
)
4,219
Effect of exchange rate changes
972
(1,267
)
Net increase in cash and cash equivalents
22,972
9,738
Cash and cash equivalents, at beginning of year
144,159
183,038
Cash and cash equivalents, at end of period
$
167,131
$
192,776
For the six months ended June 27, 2025 net cash used in operating activities consisted of $71.0 million net loss; partially offset by $24.5 million in non-cash items primarily related to impairment on fixed assets and operating leases and stock-based compensation expenses, partially offset by deferred income taxes, and $13.5 million in working-capital changes primarily related to changes in accounts receivable, partially offset by changes in inventories. For the six months ended June 28, 2024 net cash provided by operating activities consisted of $21.5 million in non-cash items primarily related to stock-based compensation expenses and net income of $4.0 million, partially offset by $14.3 million in working-capital changes due partially to capitalization of cloud-based software.
For the six months ended June 27, 2025, net cash provided by investment activities was $60.5 million which consisted of $77.6 million in proceeds from the maturities of investments AFS, partially offset by $14.7 of purchases of investments AFS. During the first half of 2025, upon maturity of investments AFS, funds were placed into money market accounts to serve as
27
liquidity for operations. For the six months ended June 28, 2024, net cash used in investment activities was $4.5 million which consisted of $20.2 million in purchases of investments AFS and $11.4 million in purchases of property, plant and equipment, partially offset by $26.4 million of proceeds from the maturity of investments AFS.
For the six months ended June 27, 2025 net cash used in financing activities was $5.5 million which primarily consisted of $4.5 million of repurchases of common stock pursuant to our share repurchase program and $1.4 million to repurchase employee common stock for taxes withheld. For the six months ended June 28, 2024, net cash provided by financing activities was $4.2 million which consisted of $5.7 million of proceeds from the exercise of stock options, partially offset by $1.4 million to repurchase employee common stock for taxes withheld.
Commitments
Employment Agreements
The Company’s Chief Executive Officer entered into an employment agreement with the Company, effective February 26, 2025. He and certain officers have as provisions of their agreements certain rights, including continuance of cash compensation and benefits, upon a “change in control,” which may include an acquisition of substantially all of its assets, or termination “without cause or for good reason” as defined in the employment agreements.
ITEM 3. QUANTITATIVE AND QUALITATI
VE DISCLOSURES ABOUT MARKET RISK
During the six months ended June 27, 2025, there have been no material changes in the Company’s qualitative and quantitative market risk since the disclosure in the Company’s Annual Report on Form 10-K for the year ended December 27, 2024.
ITEM 4. CONTROLS
AND PROCEDURES
Disclosure Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of the disclosure controls and procedures of the Company. Based on that evaluation, our CEO and CFO concluded, as of the end of the period covered by this quarterly report on Form 10-Q, that our disclosure controls and procedures were effective. For purposes of this statement, the term “disclosure controls and procedures” means controls and other procedures of the Company that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including the CEO and the CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud or material errors. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations on all internal control systems, our internal control system can provide only reasonable assurance of achieving its objectives and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of internal control is also based in part upon certain assumptions about the likelihood of future events, and can provide only reasonable, not absolute, assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in circumstances, or the degree of compliance with the policies and procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended June 27, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
28
PART II – OTHE
R INFORMATION
ITEM 1. LEGAL
PROCEEDINGS
From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of business. These legal proceedings and other matters may relate to, among other things, contractual rights and obligations, employment matters, or claims of product liability. The Company maintains insurance coverage for various matters, including product liability and certain securities claims. While the Company does not believe that any of the claims known is likely to have a material adverse effect on the Company’s financial condition or results of operations, new claims or unexpected results of existing claims could lead to significant financial harm.
ITEM 1A. RIS
K FACTORS
Our short and long-term success is subject to many factors that are beyond our control. Investors and prospective investors should consider carefully information contained in this report and the risks and uncertainties described in “Part I—Item 1A—Risk Factors” of the Company’s Form 10-K for the fiscal year ended December 27, 2024. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results. The following risk factors represent new risks that have emerged since the filing of the Company’s Form 10-K for the fiscal year ended December 27, 2024.
The announcement and pendency of our proposed acquisition by Alcon could adversely impact our business, financial condition, and results of operations.
On August 4, 2025, we entered into the Merger Agreement. Uncertainty about the effect of the Merger on our employees, customers, and other parties may have an adverse effect on our business, financial condition, and results of operations regardless of whether the Merger is completed. These risks to our business include the following, all of which could be exacerbated by a delay in the completion of the Merger:
•
the impairment of our ability to attract, retain, and motivate our employees, including key personnel;
•
the diversion of significant management time and resources toward the completion of the Merger;
•
difficulties maintaining relationships with customers, suppliers, and other business partners;
•
delays or deferments of certain business decisions by our customers, suppliers, and other business partners;
•
the inability to pursue alternative business opportunities or make appropriate changes to our business because the Merger Agreement requires us to use commercially reasonable efforts to carry on its business in the ordinary course of business and preserve intact its material business organization and existing relationships;
•
litigation relating to the Merger and the costs related thereto; and
•
the incurrence of significant costs, expenses, and fees for professional services and other transaction costs in connection with the Merger.
The completion of the Merger is subject to certain closing conditions, including stockholder approval and certain regulatory conditions, which may not be satisfied on a timely basis or at all, and the failure to consummate the Merger within the expected timeframe or at all could adversely impact our business, financial condition, and results of operations.
The obligations of the Company, Alcon and Merger Sub to consummate the transactions contemplated by the Merger Agreement are subject to the satisfaction or waiver of a number of conditions, including the adoption of the Merger Agreement by holders of a majority of the Company’s outstanding shares of common stock. Ownership of our common stock is currently concentrated among a few investors, and our largest investor currently beneficially owns approximately 27% of our outstanding shares of common stock. If our largest investors do not vote their shares in support of the adoption of the Merger Agreement, our ability to satisfy this closing condition would be materially adversely affected.
In addition, the Merger is subject to the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as the receipt of regulatory approvals in other jurisdictions, including China and Japan. The relevant governmental entities may impose requirements, limitations or costs or place restrictions on the conduct of our or Alcon’s business following the Merger as a condition to approval or not grant approval at all.
Other conditions that must be satisfied or waived before one or more of the parties will be obligated to consummate the Merger are (1) the accuracy of the other party’s representations and warranties, subject to certain materiality standards set forth
29
in the Merger Agreement; (2) compliance by the other party in all material respects with such other party’s obligations under the Merger Agreement, (3) the absence of any law or order prohibiting consummation of the Merger in specified jurisdictions in which the Company, Alcon or their respective subsidiaries have business operations; and (4) in the case of Alcon’s and Merger Sub’s obligation to consummate the Merger, a condition that there has not occurred a material adverse effect on the Company since the date of the Merger Agreement that is continuing.
We can provide no assurance that the closing conditions will be fulfilled (or waived, if applicable) in a timely manner or at all, and, if all closing conditions are timely fulfilled (or waived, if applicable), we can provide no assurance as to the terms, conditions, and timing of the completion of the Merger. Many of the conditions to completion of the Merger are not within either our, Alcon’s or Merger Sub’s control, and we cannot predict when or if these conditions will be fulfilled (or waived, if applicable).
The Merger Agreement also includes termination provisions for both the Company and Alcon. If the Merger Agreement is terminated under specified circumstances, the Company may be required to pay Alcon a termination fee of up to $43.4 million, and if the Merger Agreement is terminated under certain circumstances, including a failure to timely receive required regulatory approvals, Alcon may be required to pay the Company a termination fee equal to $72.4 million.
There can be no assurance that a remedy will be available to us in the event of a breach of the Merger Agreement by Alcon or its affiliates or that we will wholly or partially recover for any damages incurred by us in connection with the Merger. A failed transaction may result in negative publicity and a negative impression of us among our customers or in the investment community or business community generally. Further, any disruptions to our business resulting from the announcement and pendency of the Merger, including any adverse changes in our relationships with our stockholders, customers, suppliers, lenders, partners, officers, employees, governmental entities, and other third parties could continue or accelerate in the event of a failed transaction. In addition, if the Merger is not completed, and there are no other parties willing and able to acquire the Company at a price of $28.00 per share or higher, on terms acceptable to us, the share price of the common stock of the Company may decline to the extent that the current market price of the common stock reflects an assumption that the Merger will be completed.
Also, we have incurred, and will continue to incur, significant costs, expenses, and fees for professional services and other transaction costs in connection with the Merger, for which we will have received little or no benefit if the Merger is not completed. Some of these fees and costs will be payable by us even if the Merger is not completed and may relate to activities that we would not have undertaken other than to complete the Merger.
For additional information related to the Merger Agreement, please refer to our Current Report on Form 8-K filed with the SEC on August 5, 2025 (the “August 5 Form 8-K”). The foregoing description of the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement attached as Exhibit 2.1 to the August 5 Form 8-K.
Lawsuits may be filed against us or our directors or officers challenging the transactions contemplated by the Merger Agreement or the Merger, which could prevent or delay the completion of the Merger or result in the payment of damages.
Litigation relating to the Merger may be filed against us or our directors or officers. Among other remedies, claimants could seek damages and/or to enjoin the Merger and the other transactions contemplated by the Merger Agreement. An adverse ruling in any such lawsuit may delay or prevent the proposed Merger from being completed. Any such actions may create uncertainty relating to the Merger and may be costly and distracting to our management.
If the Merger is not consummated for any reason, litigation could be filed in connection with the failure to consummate the Merger.
30
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table summarizes the Company’s share repurchase activity for the three months ended June 27, 2025, on a monthly basis:
Period
Total Number of Shares (or Units) Purchased
Average Price Paid per Share (or Unit)
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number (or Approximate Dollar Value) of Shares that may yet to be Purchased Under the Plans or Programs (in thousands)
(1)
March 29 - April 25, 2025
—
$
—
—
$
30,000
April 26 - May 23, 2025
—
—
—
30,000
May 24 - June 27, 2025
260,515
17.17
260,515
25,521
Total
260,515
260,515
(1)
On May 16, 2025, the Company announced that its Board of Directors authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. During the quarter ended June 27, 2025 the Company purchased 260,515 shares for an aggregate of $4.5 million. As of June 27, 2025, approximately $25.5 million remained available for repurchases pursuant to our share repurchase program. Under the share repurchase program, the Company may repurchase shares in the open market, through privately negotiated transactions, by entering into structured repurchase agreements with third parties, by making block purchases, and/or pursuant to Rule 10b5-1 trading plans. The timing, manner, price, and amount of any repurchases under the program will be determined by the Company in its discretion, subject to market conditions, legal requirements, and other considerations. The Company is not obligated to repurchase any specific number of shares, and the program may be modified, suspended, or discontinued at any time, without prior notice.
ITEM 4. MINE SAF
ETY DISCLOSURES
Not Applicable.
ITEM 5. OTHER
INFORMATION
(c)
Trading Plans
During the quarter ended June 27, 2025
, no director or officer
adopted
or
terminated
:
(i)
Any contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense conditions of Rule 10b5-1(c); and
(ii)
Any “non-Rule 10b5-1 trading arrangement” as defined in paragraph (c) of item 408(a) of Regulation S-K.
Amended and Restated Bylaws
(incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the Commission on March 17, 2025).
Financial statements from the quarterly report on Form 10-Q of STAAR Surgical Company for the quarter ended June 27, 2025 formatted in Inline Extensible Business Reporting Language (iXBRL), are filed herewith and include: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 27, 2025, has been formatted in Inline XBRL with applicable taxonomy extension information contained in Exhibit 101.
#
Management contract or compensatory plan, contract or arrangement.
*
Filed herewith.
**
Certification furnished herewith solely to accompany this annual report pursuant to 18 U.S.C. Section 1350. Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
32
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
STAAR SURGICAL COMPANY
Dated:
August 6, 2025
By:
/s/ DEBORAH ANDREWS
Deborah Andrews
Chief Financial Officer
(on behalf of the Registrant and as its principal financial officer)
Insider Ownership of STAAR SURGICAL CO
company Beta
Owner
Position
Direct Shares
Indirect Shares
AI Insights
Summary Financials of STAAR SURGICAL CO
Beta
(We are using algorithms to extract and display detailed data. This is a hard problem and we are working continuously to classify data in an accurate and useful manner.)